SecondWave Systems is a Minneapolis-based medical device startup pioneering wearable, non-invasive focused ultrasound therapeutics for inflammatory and autoimmune diseases. Founded in 2019 by Anuj Bhardwaj, Jeff Heyman, and Professor Hubert Lim of the University of Minnesota, the company grew from industrial ultrasound expertise at The Ultran Group and academic neuromodulation research at the UMN SONIC Lab.

The platform uses low-intensity focused ultrasound delivered through a wearable device worn externally to target the splenic nerve and other autonomic pathways involved in regulating systemic inflammation. The mechanism modulates the inflammatory reflex arc, the neural pathway connecting the brain, vagus nerve, and spleen, without pharmacological intervention. A first-in-human pilot study in rheumatoid arthritis showed significant disease activity reduction. The company has also explored applications in Long COVID.

SecondWave has secured over $15 million in government funding from NIH, DARPA, and ARPA-H, and closed a $7 million Series A in April 2025. It has joined Johnson & Johnson's JLABS incubator and the Fogarty Innovation Company Accelerator Program. The company received a non-significant risk designation from the FDA in 2021 enabling faster progression to human trials.